[Illogical association nalmefene and opioids: Analysis in the French pharmacovigilance database].
Association illogique nalméfène et opioïdes : analyse dans la base française de pharmacovigilance.
Contraindication
Contre-indication
Nalmefene
Nalméfène
Opioids
Opioïdes
Pharmacovigilance
Journal
Therapie
ISSN: 1958-5578
Titre abrégé: Therapie
Pays: France
ID NLM: 0420544
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
13
11
2017
revised:
27
06
2018
accepted:
29
06
2018
pubmed:
11
9
2018
medline:
28
12
2019
entrez:
11
9
2018
Statut:
ppublish
Résumé
Nalmefene, an opioid antagonist, causes withdrawal syndromes in patients exposed to an opioid agonist. Despite its contraindication, this illogical drug association persists, especially with opioid substitution drugs (ODS). We measured the benefits of the modification in the summary of product characteristics (SPC) in March 2015 and the package leaflet of Selincro We analyzed the observations regarding a use of nalmefene with an opioid between September 2014 and August 2017 in the French pharmacovigilance database and the laboratory. The combination nalmefene and methadone was reported in about half of the cases (46/90). Observations were highest between October 2015 and March 2016 (29/90) and then decreased. Those with self-medication have increased. From October 2016, declarations become rarer. The effect of modifications in the SPC and the package leaflet on the use of nalmefene with ODS was real and progressive.
Identifiants
pubmed: 30197228
pii: S0040-5957(18)30128-8
doi: 10.1016/j.therap.2018.06.004
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Narcotic Antagonists
0
Naltrexone
5S6W795CQM
nalmefene
TOV02TDP9I
Methadone
UC6VBE7V1Z
Types de publication
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
369-374Informations de copyright
Copyright © 2018 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.